These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7161336)

  • 1. Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone.
    Peng YM; Ormberg D; Alberts DS; Davis TP
    J Chromatogr; 1982 Dec; 233():235-47. PubMed ID: 7161336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography.
    Ehninger G; Proksch B; Schiller E
    J Chromatogr; 1985 Jul; 342(1):119-27. PubMed ID: 4044741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ion-paired high-performance liquid chromatographic determination of mitoxantrone in physiological fluids.
    van Belle SJ; Schoemaker TJ; Verwey SL; Paalman AC; McVie JG
    J Chromatogr; 1985 Jan; 337(1):73-80. PubMed ID: 3980659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel assay method for mitoxantrone in plasma, and its application in cancer patients.
    Hu OY; Chang SP; Song YB; Chen KY; Law CK
    J Chromatogr; 1990 Nov; 532(2):337-50. PubMed ID: 2084130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection.
    Choi KE; Sinkule JA; Han DS; McGrath SC; Daly KM; Larson RA
    J Chromatogr; 1987 Sep; 420(1):81-8. PubMed ID: 3667832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of differential sensitivity of normal marrow myeloid progenitor cells to anthracene derivatives.
    Bron D; Dodion P; Rozencweig M; Delforge A; Mattelaer MA; Kenis Y; Stryckmans P
    Invest New Drugs; 1986; 4(1):11-6. PubMed ID: 3700036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro.
    Drewinko B; Yang LY; Barlogie B; Trujillo JM
    Cancer Res; 1983 Jun; 43(6):2648-53. PubMed ID: 6850582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
    Bowden GT; Roberts R; Alberts DS; Peng YM; Garcia D
    Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and metabolism of mitoxantrone in man.
    Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
    Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid.
    Davis TP; Peng YM; Goodman GE; Alberts DS
    J Chromatogr Sci; 1982 Nov; 20(11):511-6. PubMed ID: 6960001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.
    Lown JW; Hanstock CC; Bradley RD; Scraba DG
    Mol Pharmacol; 1984 Jan; 25(1):178-84. PubMed ID: 6708933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation.
    Johnson JL; Ahmad A; Khan S; Wang YF; Abu-Qare AW; Ayoub JE; Zhang A; Ahmad I
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jan; 799(1):149-55. PubMed ID: 14659447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.
    Cowan JD; Von Hoff DD; Clark GM
    Invest New Drugs; 1983; 1(2):139-44. PubMed ID: 6678863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of mitoxantrone in cancer patients.
    Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
    Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene.
    Polverini PJ; Novak RF
    Biochem Biophys Res Commun; 1986 Nov; 140(3):901-7. PubMed ID: 2430572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive and simple high-performance liquid chromatographic method for the determination of mitoxantrone in plasma.
    Slørdal L; Andersen A; Warren DJ
    Ther Drug Monit; 1993 Aug; 15(4):328-33. PubMed ID: 8236369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunoassay for mitoxantrone, a new antitumor agent.
    Nicolau G; Szucs-Myers V; McWilliams W; Morrison J; Lanzilotti A
    Invest New Drugs; 1985; 3(1):51-6. PubMed ID: 3988457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.
    Lu K; Savaraj N; Loo TL
    Cancer Chemother Pharmacol; 1984; 13(1):63-6. PubMed ID: 6733844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
    Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
    J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved LC assay for the determination of mitozantrone in plasma: analytical considerations.
    Priston MJ; Sewell GJ
    J Pharm Biomed Anal; 1994 Sep; 12(9):1153-62. PubMed ID: 7803567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.